Klin Farmakol Farm. 2010;24(1):38-46

Metastasizing of kidney carcinoma - current treatment possibilities

Petr Beneš
Onkologická klinika, FN Olomouc

Malignant disease of the kidneys represents about 2–3 % of all malignant diseases and their incidence in the Czech Republic is the

highest worldwide. Treatment of kidney carcinoma depends on its clinical stage and the patient’s overall condition. Surgical treatment

– nephrectomy – still is a basis for treating patients with a metastatic carcinoma of the kidneys. Current possibilities of systemic

treatment of patients with a metastatic disease lie in applying molecular biological treatment. Tyrozinkinase inhibitors VEGF of the

receptor (sorafenib, sunitinib) are used, monoclonal antibodies VEGF (bevacizumab) or mTOR kinasa inhibitors (temsirolim, everolim)

and other agents are promising.

Keywords: kidney carcinoma, metastasis, nephrectomy, tyrokinase inhibitors, monoclonal antibodies, mTOR kinase inhibitors

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Beneš P. Metastasizing of kidney carcinoma - current treatment possibilities. Klin Farmakol Farm. 2010;24(1):38-46.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int., 2001; 88 (8): 818-824. Go to original source... Go to PubMed...
    2. Ries LAG, Eisner MP, Kosary CL, et al. (Eds.) SEER Cancer Statistics Review, 1973-1997. Bethesda, Maryland: National Cancer Institute, 2000.
    3. Landis SH, Murray T, Bolden S, et al. Cancer statistics: 1999. CA Cancer J Clin, 1999; 49: 8-31. Go to original source... Go to PubMed...
    4. Bukowski RM, Wood, LS. Renal cell carcinoma: state of the art diagnosis and treatment. Clin Oncol 2007; 10: 11-22.
    5. Petruželka L. Sunitinib v léčbě karcinomu ledviny. Remedia, 2007; 17: 211-215.
    6. Tosaka A, Ohya K, Yamada K, et al. Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. J Urol, 1990; 144 (5): 1097-1099. Go to original source... Go to PubMed...
    7. Kolcová V, Geryk E, Jechová M. Zhoubné novotvary - Česká republika a vybrané státy. Praha: Galén, 1999: 45.
    8. ÚZIS ČR: Zdravotnická statistika. Novotvary 2000 ČR. Praha, 2004.
    9. Konnak JW, Grossman HB. Renal cell carcinoma as an incidental finding. J Urol, 1985; 134: 1094-1096. Go to original source... Go to PubMed...
    10. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer, 1971; 28: 1165-1177. Go to original source...
    11. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology, 1998; 51 (2): 203-205. Go to original source... Go to PubMed...
    12. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA, 1999; 281: 1628-1631. Go to original source... Go to PubMed...
    13. Ries LAG, Eisner MP, Kosary CL, et al. (Eds.) SEER Cancer Statistics Review, 1973-1997. Bethesda, Maryland: National Cancer Institute, 2000.
    14. Robson CJ. Radical nephrectomy for renal cell carcinoma. J Urol, 1963; 89: 37-41. Go to original source... Go to PubMed...
    15. Motzer RJ, Bander NH, Nanus DM. Rena-cell carcinoma. N Engl J Med, 1996; 335: 865-875. Go to original source... Go to PubMed...
    16. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol, 1999; 17: 2859-2867. Go to original source... Go to PubMed...
    17. Flanagan RC, Blumenstein BA, Salmon S, Crawford E. Cytoreduction nephrectomy in metastatic renal cancer: the results of southwest oncology group trial 8949. Proc ASCO 2000: 3.
    18. Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-2266. Go to original source... Go to PubMed...
    19. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 1995; 76: 824-832. Go to original source...
    20. Yfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14: 2410-2411. Go to original source... Go to PubMed...
    21. Godley PA, Ataga KI. Renal cell carcinoma. Curr Opin Oncol 2000; 12: 260-264. Go to original source... Go to PubMed...
    22. Wagle DG, Scal DR. Renal cell carcinoma - a review of 256 cases. J Surg Oncol 1970; 2: 23-32. Go to original source... Go to PubMed...
    23. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417. Go to original source... Go to PubMed...
    24. Motzer RJ, Schwartz L, Law TM, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13: 1950-1957. Go to original source... Go to PubMed...
    25. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980. Go to original source... Go to PubMed...
    26. Atzpodien J, et al. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 2002; 95: 1045. Go to original source... Go to PubMed...
    27. Giorgio P, Piva L, Boracchi P, et al. Adjuvant interferon to radical nephrectomy in Robson´s stage II and III renal cell carcinoma: contradictory results in pN0 and pN1 patients. Proc ASCO 1999: 18.
    28. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys, 1987; 13: 665-672. Go to original source... Go to PubMed...
    29. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35. Go to original source... Go to PubMed...
    30. Motzer R, Rini B, Michaelson MD, et al. Sunitinib malate (SU11248) shows antitumor acitivity in patients with metastatic renal cell carcinoma: updated results from phase II trials. Eur J Cancer, 2005; 3 (Suppl. 2), 227 (Abstr 797). Go to original source...
    31. Motzer RJ, Rini B, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2005; 23: 380 (Abstr 4508). Go to original source...
    32. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35. Go to original source... Go to PubMed...
    33. Motzer R, Rini B, Michaelson MD, et al. Sunitinib malate (SU11248) shows antitumor acitivity in patients with metastatic renal cell carcinoma: updated results from phase II trials. Eur J Cancer, 2005; 3 (Suppl. 2), 227 (Abstr 797). Go to original source...
    34. Petruželka L. Sorafenib. Remedia, 2007; 17: 216-222. Go to original source...
    35. Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res, 2004; 64: 7099-7109. Go to original source... Go to PubMed...
    36. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 2006; 98: 326-334. Go to original source... Go to PubMed...
    37. Haan O, Stadler W. Sorafenib. Curr Opin Oncol 2006; 18: 615-621. Go to original source... Go to PubMed...
    38. Flaherty KT. Sorafenib in renal cell carcinoma. Clin Cancer Res, 2007; 13: 747-752. Go to original source... Go to PubMed...
    39. Larkin JMG, Eisen T. Renal cell carcinoma and the use of sorafenib. Therapeutics and clinical risk management, 2006; 2: 87-98. Go to PubMed...
    40. Kane RC, Farrell AT, Haleh S, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res, 2006; 12: 7271-7280. Go to original source... Go to PubMed...
    41. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebocontrolled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512. Go to original source... Go to PubMed...
    42. Szczylik C, Temkov T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. Proc Am Soc Clin Oncol 2007; 25S: 241. Go to original source...
    43. Escudier B, Eisen T, Stadlerw M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. Go to original source... Go to PubMed...
    44. Mayer O. Sorafenib v léčbě renálního karcinomu. Farmakoterapie 2007; 3: 114-115.
    45. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev, 1997; 18: 4-25. Go to original source... Go to PubMed...
    46. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850. Go to original source... Go to PubMed...
    47. Escudier B, Pluzanska A, Koralewski P, et al.Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet, 2007; 370: 2103-2111. Go to original source... Go to PubMed...
    48. Rini BI, Halabi S, Rosonberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428. Go to original source... Go to PubMed...
    49. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon alfa2a is aktive in patiens with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-1476. Go to original source... Go to PubMed...
    50. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon alfa or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. Go to original source... Go to PubMed...
    51. Motzer J, Hudes G, Curti B, et al. Phase I/II trial of tensirolimus combined with interferon alfa for advanced renal cell carcinoma, J Clin Oncol 2007; 25: 3958-3964. Go to original source... Go to PubMed...
    52. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456. Go to original source... Go to PubMed...
    53. Hutson TE, Bukowski RM. A phase II study of GW786034 using a randomized discontinuation design in patiens with locally recurrent or metastatic clear-cell renal cell carcinoma. Clin Genitourin Cancer 2006; 4: 296-298. Go to original source... Go to PubMed...
    54. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8: 975-984. 52. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.